Treatment of Anxiety and Depression-Related Vertigo and Dizziness with SSRIs and SNRIs

DOI 12 Citations 8 References
  • Goto Fumiyuki
    Department of Otorhinolaryngology, Hino Municipal Hospital Department of Otorhinolaryngology, Keio University School of Medicine
  • Araki Yasutomo
    Department of Otorhinolaryngology, Keio University School of Medicine
  • Saito Akira
    Department of Otorhinolaryngology, Saitama Social Insurance Hospital
  • Kunihiro Takanobu
    Department of Otorhinolaryngology, Keio University School of Medicine
  • Ogawa Kaoru
    Department of Otorhinolaryngology, Keio University School of Medicine

Bibliographic Information

Other Title
  • 精神疾患に関連しためまいに対する新しい抗うつ薬による治療成績

Search this article

Abstract

Recently, vertigo or dizziness has been linked to abnormal serotonin regulation in the hippocampus. According to the DSM-VI and ICD-10, vertigo or dizziness is a common symptom of anxiety disorder, somatoform disorder, and depression. In today's stressful society, we are now observing record increases in the number of patients with depression. Because of this increase, otolaryngologists are now encountering an increasing number of patients with depression-related dizziness or vertigo.<BR>We treated 41 patients with depression-related vertigo or dizziness with a selective serotonin reuptake inhibitor (SSRI: paroxetine or fluvoxamine) or a selective norepinephrine reuptake inhibitor (SNRI: milnacipran). We graded the effects of treatment according to three levels: outstanding, effective, or not effective.<BR>Besides dizziness, the chief complaints of patients we treated were problems with sleep, headache, heavy headedness, shoulder stiffness, and loss of motivation. Drug effectiveness or the overall recovery rate was defined as the ratio of the number of patients showing outstanding and effective improvements to the total number of patients treated with a particular drug. The overall recovery rate for patients treated with paroxetine was 82% (14/17), for patients treated with fluvoxamine it was 90% (10/11), and for patients treated with milnacipran it was 62% (8/13). Side effects were observed in 22% (9/41) of the patients. Symptoms disappeared in about 2 weeks after drug treatment began.<BR>SSRIs and SNRIs are now the drugs-of-choice for treating anxiety- or depressionrelated vertigo because they are associated with fewer adverse effects than traditional antidepressants. Moreover, when compared to tranquilizers, SSRIs and SNRIs tend to be less habit-forming. As an adjunct to psychological counseling, dizziness associated with psychiatric disorders can also be treated in otolaryngological outpatient clinics with relevant drugs.To effectively treat these dizzy patients, collaboration between the patients' otolaryngologists and psychiatrists or psychological counselors is also important.

Journal

  • Equilibrium Research

    Equilibrium Research 65 (1), 17-23, 2006

    Japan Society for Equilibrium Research

Citations (12)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top